PCN127 COMPARISON OF PARTITIONED SURVIVAL VERSUS MARKOV COHORT MODELING APPROACHES IN THE EVALUATION OF COST-EFFECTIVENESS OF BLINATUMOMAB VERSUS CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST HEMATOLOGICAL COMPLETE REMISSION WITH MINIMAL RESIDUAL DISEASE